Phase 2 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to understand the study and are willing to sign a written consent form
- People aged 18 to 80 years old
- People whose general physical ability and daily functioning falls within an acceptable range, as measured by a standard oncology scale (confirm with trial site)
- People whose cancer has been confirmed by a tissue or cell sample to be advanced pancreatic adenocarcinoma (a specific type of pancreatic cancer)
- People who have not yet received any cancer treatment
- People whose blood test results for three specific cancer markers (CA19-9, CEA, and CA125) are at or below set threshold levels (confirm with trial site)
- People who have at least one tumour that can be measured using standard imaging criteria
- People whose life expectancy is estimated to be at least 3 months
- People whose kidneys, liver, and other organs are functioning adequately based on blood tests
- People who agree to use reliable contraception throughout the study, if there is any possibility of pregnancy
Who may not be able to join:
- People who are pregnant or currently breastfeeding
- People who have already received any form of cancer treatment
- People whose blood test results for the three cancer markers (CA19-9, CEA, or CA125) are above the set threshold levels
- People whose cancer type has been confirmed by pathology to be something other than adenocarcinoma of the pancreas
- People who have inflammation of the digestive tract, such as pancreatitis, cholecystitis, or cholangitis
- People with severe or uncontrolled health conditions that could affect their ability to follow the study procedures or affect the study results
- People with kidney insufficiency or who are on dialysis
- People with other serious illnesses that the research team believes could put them at significant risk during treatment
- People with a known allergy to oxaliplatin or other chemotherapy drugs used in the trial
- People who are unwilling or unable to follow the study procedures
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Guopei Luo, MD, Fudan University
Phone: 86 64175590
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall survival，OS
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.